224 related articles for article (PubMed ID: 21350830)
41. Low-dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long-term outcome from a single center experience.
Sciumè M; Vincenti D; Reda G; Orofino N; Cassin R; Giannarelli D; Gaidano G; Rossi D; Cortelezzi A
Am J Hematol; 2015 Nov; 90(11):970-4. PubMed ID: 26201283
[TBL] [Abstract][Full Text] [Related]
42. Alemtuzumab for B-cell chronic lymphocytic leukemia.
Hadj Tahar A
Issues Emerg Health Technol; 2005 Mar; (66):1-4. PubMed ID: 15806747
[TBL] [Abstract][Full Text] [Related]
43. Efficacy of alemtuzumab in cutaneous chronic lymphocytic leukaemia involving facial skin.
Grey M
Br J Haematol; 2008 Jul; 142(1):1. PubMed ID: 18477054
[No Abstract] [Full Text] [Related]
44. In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia.
De Decker M; Bacher K; Thierens H; Slegers G; Dierckx RA; De Vos F
Nucl Med Biol; 2008 Jul; 35(5):599-604. PubMed ID: 18589304
[TBL] [Abstract][Full Text] [Related]
45. Advances in the use of alemtuzumab in CLL.
Stilgenbauer S
Clin Adv Hematol Oncol; 2008 Jan; 6(1):23-4. PubMed ID: 18322437
[No Abstract] [Full Text] [Related]
46. EBV negative Richter's syndrome from a coexistent clone after salvage treatment with alemtuzumab in a CLL patient.
Janssens A; Berth M; De Paepe P; Verhasselt B; Van Roy N; Noens L; Philippé J; Offner F
Am J Hematol; 2006 Sep; 81(9):706-12. PubMed ID: 16838338
[TBL] [Abstract][Full Text] [Related]
47. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.
Alinari L; Lapalombella R; Andritsos L; Baiocchi RA; Lin TS; Byrd JC
Oncogene; 2007 May; 26(25):3644-53. PubMed ID: 17530018
[TBL] [Abstract][Full Text] [Related]
48. Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL).
Thieblemont C; Bouafia F; Hornez E; Dumontet C; Tartas S; Antal D; Lemieux B; Traullé C; Espinouse D; Salles G; Coiffier B
Leuk Lymphoma; 2004 Apr; 45(4):711-4. PubMed ID: 15160944
[TBL] [Abstract][Full Text] [Related]
49. The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53.
Osuji NC; Del Giudice I; Matutes E; Wotherspoon AC; Dearden C; Catovsky D
Haematologica; 2005 Oct; 90(10):1435-6. PubMed ID: 16219582
[TBL] [Abstract][Full Text] [Related]
50. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial.
Elter T; Borchmann P; Schulz H; Reiser M; Trelle S; Schnell R; Jensen M; Staib P; Schinköthe T; Stützer H; Rech J; Gramatzki M; Aulitzky W; Hasan I; Josting A; Hallek M; Engert A
J Clin Oncol; 2005 Oct; 23(28):7024-31. PubMed ID: 16145065
[TBL] [Abstract][Full Text] [Related]
51. Alemtuzumab (Millennium/ILEX).
Dumont FJ
Curr Opin Investig Drugs; 2001 Jan; 2(1):139-60. PubMed ID: 11527007
[TBL] [Abstract][Full Text] [Related]
52. Mycobacterium avium complex infection after alemtuzumab therapy for chronic lymphocytic leukemia.
Saadeh CE; Srkalovic G
Pharmacotherapy; 2008 Feb; 28(2):281-4. PubMed ID: 18225973
[TBL] [Abstract][Full Text] [Related]
53. A case report of successful alemtuzumab treatment of a B-CLL patient suffering from renal failure.
Haslbauer F
Ann Hematol; 2009 Apr; 88(4):399-400. PubMed ID: 19099306
[No Abstract] [Full Text] [Related]
54. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
Lemery SJ; Zhang J; Rothmann MD; Yang J; Earp J; Zhao H; McDougal A; Pilaro A; Chiang R; Gootenberg JE; Keegan P; Pazdur R
Clin Cancer Res; 2010 Sep; 16(17):4331-8. PubMed ID: 20601446
[TBL] [Abstract][Full Text] [Related]
55. Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia.
Osterborg A; Mellstedt H; Keating M
Med Oncol; 2002; 19 Suppl():S21-6. PubMed ID: 12180488
[TBL] [Abstract][Full Text] [Related]
56. Successful treatment of steroid resistant autoimmune thrombocytopenia associated with chronic lymphocytic leukemia with alemtuzumab.
Ammatuna E; Marino C; Mitra ME; Calvaruso G; Iannitto E
Eur J Haematol; 2004 Sep; 73(3):225-6. PubMed ID: 15287923
[No Abstract] [Full Text] [Related]
57. Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation.
Karlsson C; Norin S; Kimby E; Sander B; Porwit Macdonald A; Nilsson B; Johansson E; Mellstedt H; Lundin J; Osterborg A
Leukemia; 2006 Dec; 20(12):2204-7. PubMed ID: 17051245
[No Abstract] [Full Text] [Related]
58. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia.
McCune SL; Gockerman JP; Moore JO; Decastro CM; Bass AJ; Chao NJ; Long GD; Vredenburgh JJ; Gasparetto C; Adams D; Payne N; Rizzieri DA
Leuk Lymphoma; 2002 May; 43(5):1007-11. PubMed ID: 12148879
[TBL] [Abstract][Full Text] [Related]
59. Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia.
Moreno C; Montillo M; Panayiotidis P; Dimou M; Bloor A; Dupuis J; Schuh A; Norin S; Geisler C; Hillmen P; Doubek M; Trněný M; Obrtlikova P; Laurenti L; Stilgenbauer S; Smolej L; Ghia P; Cymbalista F; Jaeger U; Stamatopoulos K; Stavroyianni N; Carrington P; Zouabi H; Leblond V; Gomez-Garcia JC; Rubio M; Marasca R; Musuraca G; Rigacci L; Farina L; Paolini R; Pospisilova S; Kimby E; Bradley C; Montserrat E
Haematologica; 2015 Apr; 100(4):511-6. PubMed ID: 25596264
[TBL] [Abstract][Full Text] [Related]
60. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study.
Delgado J; Thomson K; Russell N; Ewing J; Stewart W; Cook G; Devereux S; Lovell R; Chopra R; Marks DI; Mackinnon S; Milligan DW;
Blood; 2006 Feb; 107(4):1724-30. PubMed ID: 16239425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
